Considering the vital role of GLUT4 in the rate-limit step of glucose transport, targeting the pathways associated with GLUT4 has thus become an attractive strategy for drug discovery against T2DM and other metabolic disorders [13], [14]. The gene discussed is SLC2A4; the disease is type 2 diabetes mellitus.